Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced −Highlights Phase 2 data for ATH434 in Multiple System ...

Early one morning, while checking on a slumbering patient at the Center for Sleep Medicine, Erik St. Louis, M.D., noticed something peculiar. The patient, a woman in her early 60's, had started ...

It’s important to know that at first, multiple myeloma may not cause any symptoms. Usually, it is only suspected after a routine blood test shows an abnormality. After the disease has progressed, ...

MONDAY, Nov. 10, 2025 (HealthDay News) — Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million people estimated to be living with ...

HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...

Jan. 9, 2025 -- Multiple sclerosis (MS) is a complex condition that affects the brain and spinal cord. How does MS impact the body? What are the symptoms of MS? We spoke with Michael Levy, MD, PhD, to ...

Takeda has given up on an AstraZeneca-partnered neurological disorder program after the therapy flunked a phase 2 study. The Japanese pharma had been evaluating the alpha-synuclein antibody, called ...

Ionis Pharmaceuticals Inc. ((IONS)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...

Parkinson’s disease (PD) and multiple system atrophy (MSA) are neurodegenerative illnesses defined by an abnormal accumulation of alpha-synuclein aggregates in neurons, nerve fibers, and glial cells ...